ARTICLE | Company News
HealthLinx, Proaegis, Monash University gastrointestinal, pulmonary news
October 22, 2007 7:00 AM UTC
Diagnostic company HTX will spin out its CR014 drug development assets into Proaegis. The peptide that has broad-spectrum activity in vascular leak is in preclinical testing to treat acute respiratory distress syndrome (ARDS) and is expected to enter Phase I testing in 12-18 months.
HTX also received rights to the university's Follistatin, which will be transferred to Proaegis. The monomer protein that binds activin is in preclinical testing to treat ulcerative colitis. Further terms of the university license were not disclosed. ...